RESEARCH TRIANGLE PARK, NC, Aug. 5 /PRNewswire-FirstCall/ - Patheon (TSX: PTI), a global provider of drug development andmanufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE(R)
"We are very excited that Dendreon has chosen Patheon to help them bring to market this promising new therapy. Our agreement is further evidence that we are being recognized in the industry as the contract development and manufacturer of choice. We have dedicated ourselves to understanding our customer's needs and developing both the capability and capacity to deliver on those needs. We're happy that Dendreon has trusted us to be part of the commercialization of this product," said Wes Wheeler, Patheon's Chief Executive Officer and President.
PROVENGE is the first autologous cellular immunotherapy to be approved by the FDA and is based on a unique technology platform.
Patheon is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, ensures that customer products can be launched timely and confidently anywhere in the world.
SOURCE Patheon Inc.
Subscribe to our Free Newsletters!
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...View All